Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study

HIV / AIDSViral Infections, Non-HIV

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Lancet Infect Dis.

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL

doi: 10.1016/

Viral Infections, Non-HIV

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Swiss Med Wkly.

Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F

doi: 10.4414/smw.2017.14543.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Hepatology.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S

doi: 10.1002/hep.29642.

Viral Infections, Non-HIV

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Swiss Med Wkly.

Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, Braun DL, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens J, The Swiss Hepatitis C Cohort Study.

doi: 10.4414/smw.2018.14560.

Further Publications Anesthesiology

Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort

Swiss Med Wkly

Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer MC, Vernazza P, Scheidegger C

doi: 10.4414/smw.2021.20460

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

HIV / AIDS

Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

Rivero-Juarez A, Tellez F, Castaño-Carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua-García M, Zapata-Lopez A, Collado A, Gómez-Vidal MA, Perez-Stachowski J, Muñoz-Medina L, Fernandez-Fuertes E, Rivero A, Grupo de estudio de Hepatitis virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

doi: 10.1111/hiv.12715.

HIV / AIDSViral Infections, Non-HIV

Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

J Int AIDS Soc.

Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB

doi: 10.7448/IAS.20.1.22146.

Viral Infections, Non-HIV

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial

Ann Intern Med.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers

doi: 10.7326/M17-0118.

Related content

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial